Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The pathogenetic role and the clinical importance of the presence of antiphospholipid antibodies (APAs) in patients with immune thrombocytopenic purpura (ITP) are not clear. In this study, the prevalence and clinical significance of APAs were investigated in patients with ITP. Eighty-two newly diagnosed ITP patients were prospectively studied. They were evaluated for the presence of lupus anticoagulant (LA) and immunoglobulin G/M anticardiolipin antibodies (ACAs). Thirty-one patients (37.8%) were APA positive at diagnosis. No statistically significant differences were found between the APA-positive and APA-negative groups regarding gender, initial platelet counts, or response to methylprednisolone therapy. After 5 years of follow-up, cumulative thrombosis-free survival of APA-positive (n = 31) and APA-negative (n = 51) ITP patients was 39% and 97.7%, respectively. A significant difference was found between these groups by log-rank test (P = .0004). In addition, LA was an important risk marker for the development of thrombosis in ITP patients. After a median follow-up of 38 months, 14 ITP patients (45%) who had APA positivity developed clinical features (thrombosis or fetal losses) of antiphospholipid syndrome (APS). There were no differences between the APA-positive patients with and without APS regarding the initial platelet counts, response to the therapy, or ACA positivity. The positivity rate for LA was significantly higher in those patients with ITP who developed APS (χ2: P = .0036; relative risk 7.15; 95% confidence interval, 1.7-47). In conclusion, this study indicates that a significant proportion of patients initially presenting with ITP and APA positivity developed APS. In patients with ITP, the persistent presence of APAs is an important risk factor for the development of APS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365 · cited 1×
“Median age, y 31 (16-70) 33 (16-66) 31 (20-70)”
Cited by
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., & Crowther, M. A. (2011) · Blood · doi:10.1182/blood-2010-08-302984 · Cited by 1,856
Pathobiology of Secondary Immune Thrombocytopenia
Cines, D. B., Liebman, H., & Stasi, R. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.12.005 · Cited by 246
Sarpatwari, A., Bennett, D., Logie, J. W., Shukla, A., Beach, K. J., Newland, A. C., Sanderson, S., & Provan, D. (2010) · Haematologica · doi:10.3324/haematol.2009.018390 · Cited by 241
“report a statistically significant difference in 5-year, thrombosis-free survival between APA-positive and negative patients.(29) Knowledge of an elevated risk of venous thrombosis among adult patients with primary immune thrombocytopenia may possibly support increased utilization of thromboprophylactic treatment in p…”
BackgroundSplenectomy for immune thrombocytopenia: down but not out
Chaturvedi, S., Arnold, D. M., & McCrae, K. R. (2018) · Blood · doi:10.1182/blood-2017-09-742353 · Cited by 202
“Although the use of splenectomy has declined substantially with the development of new medical therapies, it remains the most cost-effective second-line treatment of ITP.”
BackgroundInfluential
Metadata
- Authors
- Diz-Küçükkaya, R., Hacıhanefioǧlu, A., Yenerel, M., Turgut, M., Keskin, H., Nalçacı, M., & l˙nanç, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-09-15
- Volume
- 98
- Issue
- 6
- Pages
- 1760-1764
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2073604625
- Cited by
- 225
- References
- 2
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. https://app.cochat.ai/papers/10.1182/blood.v98.6.1760
- The paper
- Diz-Küçükkaya, R., Hacıhanefioǧlu, A., Yenerel, M., Turgut, M., Keskin, H., Nalçacı, M., & l˙nanç, M. (2001). Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. https://doi.org/10.1182/blood.v98.6.1760
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.